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We expressed the C-terminal 99 amino acids of chicken gizzard caldesmon (658C) and two point mutants in which the preferred phosphorylation 
sites of MAP kinase and ~34’~” kinase. Se?“‘ and Thr673 were altered to aspartic acid The T673D mutant was mdtstmguishable from 658C but 
S702D was not phosphorylated by MAP kinase. was significantly less potent as an inhtbitor of actintropomyosin activation of myosin MgATPase. 
and bound less actintropomyosin at low concentrations Thus Ser ‘“’ is involved in the tropomyosm-dependent inhtbttory mechanism of caldesmon. 
and Its phosphorylatton by MAP kmase or ~34’~” kinase could modulate caldesmon function. 
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1. INTRODUCTION 
In smooth muscle and non-muscle cells Ca” controls 
myosin filament activity via the Cacalmodulin-de- 
pendent myosin light-chain kinase which activates 
myosin by phosphorylation. In addition, the thin fila- 
ments, which contain actin, tropomyosin, caldesmon 
and a calcium binding protein, are also Ca’+ regulated. 
In vitro both native thin filaments and synthetic sys- 
tems, consisting of actin, tropomyosin, caldesmon and 
calmodulin at ratios similar to native thin filaments, are 
effectively regulated by Ca’+ in a manner formally anal- 
ogous to the regulatory function of troponin in striated 
muscles [1,2]. Caldesmon is a very potent inhibitor of 
actomyosin ATPase activity; inhibition of actin activa- 
tion of myosin MgATPase activity by over 90% is com- 
monly observed with fewer than one caldesmon mole- 
cule bound to every ten actin monomers and Ca’+ and 
calmodulin, or a calcium binding protein can reverse 
this inhibition [1,3,4]. 
In order to understand the molecular mechanism of 
caldesmon regulation we obtained a chicken gizzard 
caldesmon cDNA [5] and expressed intact caldesmon 
and a series of mutants in E. coli [6]. We found that the 
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entire regulatory function of caldesmon resides in an 
expressed fragment, 658C. consisting of the C-terminal 
99 amino acids (domain 4b) [3.6-81. 
Further modulation of caldesmon function may 
occur as a consequence of phosphorylation. Caldesmon 
is a substrate for many kinases in vitro; however, the 
only kinases for which there is evidence of caldesmon 
phosphorylation in vivo are the proline-directed ki- 
nases, p34 cdc’ in non-muscle tissue [9.10] and MAP ki- 
nase in smooth muscle [11,12]. 
The consensus sequence for ~34’~” kinase is (Serl 
Thr)-Pro-X-Z in which X is a polar amino acid and Z 
is normally a basic residue [13]; inspection of the cal- 
desmon sequence located only one such site occurring 
at residues 673-676 (Thr-Pro-Asn-Lys) which is within 
the 658C fragment (the numbering is from the chicken 
gizzard CDh/3 sequence of Bryan et al [5,7]). Experimen- 
tally five in vitro p34cdc’ kinase sites have been identi- 
fied: Se?“, Serb6’, Thr673, Thr6”‘j and Ser”‘; a!1 of these 
amino acids are adjacent to proline, however, the Thr673 
site was found to have at least twice as much phosphate 
incorporated as any other [14]. Phosphorylation of cal- 
desmon by ~34”~~’ kinase has been shown to inhibit 
actin and calmodulin binding to both non-muscle [15] 
and smooth muscle [16] caldesmon. 
In vitro the predominant MAP kinase phosphoryla- 
tion site observed experimentally was Ser”” [12]. Such 
phosphorylation results in a small decrease in actin 
binding and has no effect on calmodulin binding [17]. 
Caldesmon phosphorylation in intact smooth muscle 
has been shown to occur at the same sites as those 
phosphorylated by MAP kinase, and MAP kinase (but 
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not ~34”~“‘) has been detected in normal smooth muscle 
cells [12,17]. 
Both Thr673 and Ser702 are in the C-terminal domain 
of caldesmon (domain 4b) which we have shown con- 
tains all its regulatory functions [6,18], and Thr673 is 
close to a putative binding site for calmodulin at 65% 
666 [7,19]. To test the possible role of phosphorylation 
of these residues in modulating caldesmon function we 
constructed and expressed mutants of the C-terminal 99 
amino acids of gizzard caldesmon in which the threo- 
nine or serine had been changed to aspartic acid. If these 
residues were the natural sites of phosphorylation, the 
mutants would not be phosphorylated. Moreover intro- 
duction of the negatively charged aspartic acid has been 
shown to mimic the effects of phosphorylation in a 
number of enzymes [20-221. Thus it might be expected 
to alter caldesmon function in the same way as phos- 
phorylation of these sites. In fact we found that modifi- 
cation of Ser702 (mutant S702D) had significant effects 
on actin binding, inhibition of actomyosin MgATPase, 
and phosphorylation by MAP kinase, but modification 
of Thr673 (mutant T673D) did not. 
2. MATERIALS AND METHODS 
2.1. Construction and expression of mutants 
The construction of the pMW 172 expresston plasmid encodmg the 
C-terminal 99 amino acids of chicken gizzard caldesmon (658C) was 
described m [6]. This was used as a template for the productron of 
point mutants by the inverse PCR method [23] Back-to-back primers 
of S-TGCTGGACTGAAAGTTGGTGT-3’ and S-GTTTCCTTA- 
TTTGGATCTCCTGTTCCCCCAGGTGATG-3’ (mutated nucleo- 
tides underlined) were used to change threonme to aspartic acid at 
positton 673 (all numbering refers to the full-length 756 amino acrd 
sequence [5]). Similarly 5’-TCTGATTTAAGACCAGGAGATGTA- 
3’ and 5’-AGGTTTTGGAGCAGGmTTTGTTACCCTCTGG-3’ 
were used to change serme to aspartic actd at position 702. Lmear 
products from the total plasmid PCR were re-circulartsed usmg T4 
DNA ligase and used to transform Ca”-competent JM 101 cells. Ex- 
pression plasmids containing the requtred mutation, named, respec- 
tively, T673D and S702D, were identified by double-stranded se- 
quencing. 
Constructs were expressed in BL21(DE3) cells and the fragments 
purified as previously described for 658C [6] 
2.2. Phosphorylation by MAP krnase 
Recombinant MAP kmase, activated by thiophosphorylation, was 
kindly supplied by Dr. Chris Marshall, Institute of Cancer research, 
London. 0.2-0.3 mg/ml caldesmon 658C and the two mutants were 
incubated with 0.004 mg/ml MAP kinase for 30-60 mm in 5 mM 
Tris-HC), pH 7.5, 11 mM MgC&. 0.18 mM EGTA, 0.27 mM Na,VO,, 
0.1% mercaptoethanol, 0.01% Brim 35.0.36 mg/ml bovine serum albu- 
min and 110 ,uM [$‘P]ATP. An aliquot of the reaction mixture was 
spotted onto Whatman P-81 paper and, after washing in 25 mM 
phosphoric acid, incorporatron of “P, into protem was determined by 
liquid scintillatton counting. Another aliquot of the sample was sepa- 
rated by SDS gel electrophoresis. 
2.3. Functional assays 
ATPase activity was determined by assaying P, released followmg 
10 min incubation of smooth muscle actin, tropomyosin and skeletal 
muscle myosin (or heavy meromyosin). The reaction was mittated by 
adding MgATP to 2 mM, and terminated with 10% trichloroacetic 
86 
acid [6]. Binding to calmodulinSepharose (Pharmacia) was per- 
formed as in [6]. The expressed proteins were covalently labelled with 
N-succinlmidyl[2,3,3H]propionate (Amersham) and their binding to 
actin-tropomyosin was assayed by co-sedtmentation, as descrtbed in 
[1] and [6]. 
3. RESULTS 
3.1. Phosphorylation by MAP kinase 
The parent C-terminal domain of caldesmon, 658C, 
and the point mutants, T673D and S702D, were ex- 
pressed at approximately equal yield and purified. On 
SDS gel electrophoresis they migrated with identical 
apparent molecular weights of 10,500 Da (Fig. 1). When 
incubated for 60 min with MAP kinase and [y3’P]ATP, 
658C and T673D incorporated similar amounts of 3’P 
whilst there was no measurable 32P incorporation into 
S702D using the filter technique. This is also shown in 
autoradiographs of the reaction mixtures following in- 
cubation with MAP kinase (Fig. 1, bottom panel); 658C 
and T673D were strongly radioactive whereas the band 
of S702D was much less radioactive. 
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Fig. 1. Phosphorylation of 658C, T673D and S702D by MAP kinase 
(Top panel) Proteins were separated by electrophorests on 0.1% SDS/ 
8-18% polyacrylamtde gradient gels (Pharmacia Excelgel) and stained 
in PAGE Blue 83 (BDHIMERCK) The quantities loaded on the gel 
were 5 ,ug T673D. 3.8 pg 658C and 3.3 pug S702D. The pure protein 
and the reaction mtxture (containmg BSA) followmg incubation wtth 
MAP kinase and [y”P]ATP are shown in adlacent lanes (Bottom 
panel) Autoradiograph of the lower part of this gel. Following mcuba- 
non with MAP kmase, 658C and T673D were phosphorylated but 
S702D was not. 
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3.2. Inhibition of actin-activated ATPase 
The C-terminal 99 amino acids of caldesmon con- 
tained in 658C have been shown to contain the tro- 
pomyosin-dependent inhibitory site of caldesmon 
[2,6,7]. None of the caldesmon fragments inhibited actin 
activation under our experimental conditions, but in the 
presence of tropomyosin, 658C inhibited actin activa- 
tion at both low (5 mM KCl) and moderate (50 mM 
KCl) ionic strengths (Fig. 2), in agreement with previ- 
ous work using 658C and whole caldesmon [2.6]. The 
mutant T673D also inhibited actin-tropomyosin activa- 
tion and was indistinguishable from 658C, but the mu- 
tant S702D was significantly less effective as an inhibi- 
tor in 50 mM KC1 (Fig. 2A). At lower ionic strength (5 
mM KCl, Fig. 2B) S702D became practically ineffective 
as an inhibitor. 
3.3. Calmodulin and actin-tropomyosin binding 
658C, T673D and S702D bound to calmodulin- 
Sepharose in the presence of Ca’+ and the three ex- 
pressed proteins were not distinguishable (Fig. 3). 
We compared the binding of 658C, T673D and 
S702D to 11 ,uM actin saturated with tropomyosin in 
the concentration range 5-50 ,LLM using quantitative 
scanning of gel electrophoresis to determine the quan- 
tity of protein co-sedimenting with actin. We could not 
see any differences between the mutants under these 
conditions. This method is reliable for measuring weak 
binding between the caldesmon peptides and actintro- 
pomyosin, but is insufficiently sensitive to enable us to 
assay the high affinity binding sites which have a stoi- 
chiometry of 0.07 per actin and which have been identi- 
A I3 
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Fig. 2 Inhibition of actin and actin-tropomyosin activatton of myosm 
MgATPase. (A) Effect of 658C (0). T673D (m) and S702D (0) on 
actin-tropomyosm-activated myosin MgATPase activity. Conditions: 
0.125 mg/ml skeletal muscle myosin, 0.5 mg/ml smooth muscle actin, 
0.2 mg/ml smooth muscle tropomyosin in 5 mM PIPES, 5 mM MgC12, 
1 mM dithiothreitol. SO mM KCl. pH 7.0, 37°C. Uninhibited ATPase 
activity = 1,100 nmol P,lmg myosin/min. (B) Effect of 658C (0) and 
S702D (0) on actin-tropomyosin-activated heavy meromyosm 
MgATPase activity at lower ionic strength. Conditions: 0.04 mg/ml 
heavy meromyosm, 0.15 mg/ml actin, 0.04 mg/ml tropomyosin, 5 mM 
PIPES, pH 7.0. 5 mM KCI, 2.5 mM Mg CL, 37°C. Uninhibited 
ATPase activity = 2,775 nmoUmg heavy meromyosm/min 
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Fig. 3. Binding to calmodulin-Sepharose. CalmodulinSepharose (10 
~1 of 50% suspension m SO ~1 total volume) was mixed with O-20 FM 
658C (II), T673D (w) and S702D (0) labelled with N-succin- 
imtdyl[2.33H]propionate in the buffer used in Ftg. 2 plus 0.1 mM 
CaCl?. Binding was determined from the radioactivity co-sedimentmg 
with the calmodulin&epharose as described in [6]. 
fied in whole caldesmon and 658C [1,6,15]. Therefore 
we also compared 658C and S702D binding to actin- 
tropomyosin after labelling them with N-succin- 
imidy1[2,3,3H]propionate at a more extended range of 
concentrations (Fig. 4). S702D bound significantly less 
than 658C at all concentrations up to 20 ,uM, but this 
was particularly pronounced at the lowest concentra- 
tions, below 1 PM, consistent with a reduction in the 
affinity of the tight binding sites (Fig. 4, inset). 
4. DISCUSSION 
4.1. Conjirmation of MAP kinase site at Ser702 in cal- 
desmon 
Under the conditions of our measurements, mutation 
of Ser702 almost completely abolished MAP kinase 
phosphorylation whilst mutation of Thr673 had hardly 
any effect (Fig. 1). Thus it appears that Ser”’ is the main 
site for the enzyme in the C-terminus of gizzard cal- 
desmon. This is compatible with previous work using 
MAP kinase. Adam et al. [l l] found that two sites in 
caldesmon were phosphorylated in canine aortas fol- 
lowing phorbol dibutyrate stimulation, Ser702 and a site 
VTS*PTKV which is at the extreme C-terminus of 
mammalian caldesmon but is absent in the gizzard cal- 
desmon we studied [5,7]. The same sites were 
phosphorylated by MAP kinase in vitro [12]. Childs et 
al. [17] noted that Thr673 was poorly phosphorylated by 
MAP kinase in vitro and suggested that the preferred 
sites in the C-terminus were at Thr6g6 and/or Ser7’*. 
4.2. Involvement of Ser7’-’ ’ m the tropomyosin-dependent 
inhibitory site 
Mutation of Ser702 to aspartate significantly reduced 
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Fig. 4. 658C and S702D binding to actm-tropomyosin. Up to 2OflM 
658C (0) or S702D (0) labelled with N-succinlmldyl[2,3-3H]proplonate 
(50-250 cpm/pmol) were mixed with a constant 11 PM F-actm in the 
presence of tropomyosin (A:tm 0.4 W/M.) at 25°C m 5 mM K?- PIPES, 
2.5 mM MgC&, 1 mM DTT, pH 7.0, and centrifuged for 20 mm m 
a Beckman Airfuge. The amount of each caldesmon fragment in the 
supernatant before and after centrlfugat~on was measured by hquld 
scmtlllation counting The ‘free’ and ‘bound’ concentration of each 
fragment was calculated as described by Smith et al. [I]. Pooled data 
from at least two experiments are shown. The hne is a best-fit of the 
658C data to a single class of bindmg sites: Kd = 6.6 f 1. I PM. B,, = 
0.71 rl: 0.05 658C bound per actin. (Inset) Low concentration range of 
the same expertments. The lines are derived from binding measure- 
ments on 658C m 161. The upper line represents the two classes of 
bmdmg sites in 658C: strong, E,,,,, = 0.027iactm. Kd = 0.11 FM plus 
weak, B,,, = 0.69/dctin, K,, = 14.9 PM The lower line represents 
weak binding with the strong bindmg component absent. Note how 
this corresponds to the data for S702D. 
the ability of 658C to inhibit actin-tropomyosin activa- 
tion of myosin MgATPase, especially at low ionic 
strength, whereas it had little effect on inhibition in the 
absence of tropomyosin (Fig. 2). It has been shown that 
inhibition of actin---tropomyosin activation is directly 
coupled to caldesmon binding to a class of high affinity 
actin-tropomyosin sites with a stoichiometry of 1 per 14 
actins [l-3]; these high affinity sites are located in the 
658C C-terminal fragment of caldesmon [2,6]. The ef- 
fect of mutation at Ser7”2 was to reduce actin-tropomy- 
osin binding and this was most pronounced at the low- 
est concentrations (Fig. 4, inset). This is consistent with 
a substantial decrease in the tight binding component 
(stoichiometry 0.07 per actin). with rather little effect 
upon the low affinity actin binding (stoichiometry 0.7-l 
per actin) which is not coupled to inhibition [3.6]. 
Ser7’* is thus implicated in the tropomyosin-depend- 
ent inhibitory mechanism of caldesmon [2]. Current ev- 
idence on the location of the sites important for inhibi- 
tion is entirely compatible with this assignment [6.18]. 
The mutation of serine to aspartate introduces a nega- 
tive charge at neutral pH, and this has been shown to 
have the same effect as phosphorylation in a number of 
different enzymes [20-221. The effect of changing Ser”’ 
of caldesmon to aspartic acid upon its actin-tro- 
pomyosin binding and inhibition (Figs. 2 and 4) is sim- 
ilar to the effect of phosphorylating caldesmon follow- 
ing both MAP kinase and ~34”~” kinase phosphoryla- 
tion [15,17]. A small effect on binding was observed in 
measurements using high concentrations of caldesmon 
[15] whilst a larger effect was noted under conditions 
where only the high affinity sites would be occupied 
[17]. This further emphasises the importance of Ser”’ as 
a site where caldesmon may be regulated by phospho- 
rylation. 
4.3. No evidence for a role of Thr”73 
Thr673 is supposed to be the preferred site of phospho- 
rylation by ~34““” kinase [14]: however mutation of this 
amino acid to aspartate did not alter the properties of 
658C (Figs. 2 and 3). ~34”“~’ kinase has been reported 
to introduce up to 4 P, per caldesmon [12]. The effect 
of p34”d”’ kinase on actin binding and caldesmon inhibi- 
tion may therefore be a consequence of phosphoryla- 
tion at Ser7”’ rather than Thrb73, or more sites may need 
to be phosphorylated to produce the observed effect 
1151. 
Thr673 is close to a sequence, MWEKGNVFS (amino 
acids 658.-666). which had been identified as a calmod- 
ulin binding site from work with isolated peptides and 
expressed fragments [7,19,24]. An effect of mutation of 
Thr6’j upon calmodulin binding might be predicted, es- 
pecially since p3Qd” kinase phosphorylation was re- 
ported to affect calmodulin binding [ 151. 
Using calmodulin-Sepharose we found that binding 
was not affected by mutation at Thrh7’ or Ser7” (Fig. 3). 
It should be noted, however. that the parent sequence 
of 658C is slightly modified in the region of the calmod- 
ulin binding site (Trph” in the wild-type changed to 
glycine [6]) and so may not have bound calmodulin 
normally anyway. We have recently obtained evidence 
for another calmodulin binding region around 670-710, 
hence the calmodulin binding we observed (Fig. 3) may 
not reflect the properties of the 658-666 sequence. 
4.4. Physiological signijicance 
This work has demonstrated that the introduction of 
a negative charge at a single amino acid, Ser7” of cal- 
desmon, significantly impairs its regulatory function. 
Caldesmon is phosphorylated in vivo and the level of 
phosphorylation increases in smooth muscle following 
stimulation by contractile agonists, particularly endo- 
thelin [25] and phorbol dibutyrate [ 11.261, and in non- 
muscle cell at mitosis [9,10]. In the smooth muscle the 
primary phosphorylation site is Ser”? 1121; in the mitotic 
cell Ser7”’ is the second most highly phosphorylated site 
[14]. Phosphorylation of serine introduces a negative 
charge to an equal or greater extent than mutation of 
serine to aspartic acid. Thus phosphorylation will im- 
pair caldesmon function (both inhibition and actin- 
myosin crosslinking [7]) by the mechanism we have 
88 
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demonstrated, and consequently may increase contrac- 
tility. 
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